GlaxoSmithKline PLC (GSK)

pos +0.00
Today's Range: 0.00 - 0.00 | GSK Avg Daily Volume: 3,780,400
Last Update: 10/06/15 - 4:02 PM EDT
Volume: 0
YTD Performance: -6.95%
Open: $0.00
Previous Close: $39.77
52 Week Range: $37.24 - $49.08
Oustanding Shares: 2,171,250,000
Market Cap: 86,763,150,000
6-Month Chart
TheStreet Ratings Grade for GSK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 3 2 2
Moderate Buy 0 0 0 0
Hold 5 4 4 5
Moderate Sell 0 1 1 1
Strong Sell 1 1 1 0
Mean Rec. 2.56 2.67 2.88 2.63
Latest Dividend: 0.57
Latest Dividend Yield: 6.16%
Dividend Ex-Date: 08/12/15
Price Earnings Ratio: 13.73
Price Earnings Comparisons:
GSK Sector Avg. S&P 500
13.73 6.80 25.03
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-5.20% -13.28% -16.06%
Revenue -18.10 -0.16 -0.06
Net Income -52.50 -0.48 -0.19
EPS -51.60 -0.45 -0.18
Earnings for GSK:
Revenue 35.81B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $0.60 $0.70 $2.39 $2.78
Number of Analysts 2 1 6 6
High Estimate $0.64 $0.70 $2.50 $3.32
Low Estimate $0.56 $0.70 $2.31 $2.59
Prior Year $0.90 $0.82 $2.84 $2.39
Growth Rate (Year over Year) -33.33% -14.63% -15.85% 16.18%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
The charts show that the stock is due for a rally.
Eli Lilly has bucked the downtrend in other pharma names, and its chart is pointed higher.
Investors have been distracted by the Fed, and that's a shame.
Not many, according to filings from Tweedy Browne and Kahn Brothers.
They should learn to trust techs, financials.
As health-care stocks rally, it's time for politicians to move on.
Have it ready in case market turns volatile.
Deals coming fast and furious in the best group in town.
Combined Heinz-Kraft heads a long second-quarter list.
Approval of malaria vaccine could provide a shot in the arm.

Columnist Conversations

I would pay attention to this one during the first hour of trading. I think the new CEO has lost all credibil...
Yum's getting ridiculous again because you have to wait for the call tomorrow and no one knows what will be sa...
My view is that the bulls have it wrong and that the preoccupation with the price momentum over the last two d...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.